Monopar Therapeutics: management transactions · United States · SEC (Form 4)

About Monopar Therapeutics

Monopar Therapeutics Inc. is a clinical-stage biotechnology company listed on the Nasdaq in the United States under the ticker MNPR. For French-, Belgian- and Swiss-based investors, it should be viewed as a healthcare micro/small-cap whose investment profile is driven primarily by clinical and regulatory catalysts rather than current commercial revenues. The company was formed in December 2014 as a Delaware limited liability company and later established its executive headquarters in Wilmette, Illinois, with its team largely based in the Chicago area in the United States. ([ir.monopartx.com](https://ir.monopartx.com/annual-reports/content/0001654954-23-005425/mnpr_10k.pdf?TB_iframe=true&height=auto&preload=false&width=auto&utm_source=openai)) Monopar’s business is currently organized around two core development pillars. First, it is advancing ALXN1840, a late-stage therapy candidate for Wilson disease, a rare inherited disorder of copper metabolism. Second, it is building a radiopharmaceutical platform for oncology, including MNPR-101-Zr for imaging advanced solid tumors, MNPR-101-Lu for treatment, and MNPR-101-Ac in late preclinical development. This positioning places Monopar at the intersection of rare disease and precision oncology, two attractive but execution-heavy segments that require disciplined capital allocation, strong clinical data, and effective regulatory engagement. ([ir.monopartx.com](https://ir.monopartx.com/press-releases/detail/130/monopar-therapeutics-reports-first-quarter-2026-financial)) From a competitive standpoint, Monopar remains a precommercial developer, so its market value depends largely on the strength of its clinical readouts, the timing of regulatory milestones, and its ability to differentiate itself against much larger pharmaceutical peers. In Wilson disease, the key question is whether ALXN1840 can deliver a compelling combination of efficacy, safety, and patient convenience that resonates with physicians, regulators, and ultimately payers. In radiopharmaceuticals, Monopar operates in a fast-moving but highly competitive category where tumor targeting, translational credibility, and manufacturing scalability matter greatly. The company describes its pipeline strategy as a mix of internal development and in-licensing of late-preclinical and clinical-stage assets, an approach intended to reduce early-stage risk and accelerate execution. ([monopartx.com](https://www.monopartx.com/?utm_source=openai)) Recent developments are particularly important. In 2024, Monopar announced an exclusive worldwide license agreement with Alexion, AstraZeneca Rare Disease for ALXN-1840, a compound that had already advanced through Phase 3. In 2026, management said the company remained on track to submit a New Drug Application to the FDA in mid-2026 and highlighted the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer to prepare for a possible launch. In its first-quarter 2026 results, Monopar reported cash, cash equivalents and investments of $137.5 million as of March 31, 2026, and stated that current funds are expected to support operations through at least December 31, 2027. The company’s ongoing SEC Form 4 filings also keep insider activity in focus for investors watching ownership changes and management alignment. ([ir.monopartx.com](https://ir.monopartx.com/press-releases/detail/105/monopar-announces-agreement-with-alexion-astrazeneca-rare?utm_source=openai))